| 18.01 -0.01 (-0.06%) | 04-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 23.88 | 1-year : | 27.89 |
| Resists | First : | 20.45 | Second : | 23.88 |
| Pivot price | 18.54 |
|||
| Supports | First : | 14.73 | Second : | 11.19 |
| MAs | MA(5) : | 18.01 |
MA(20) : | 18.01  |
| MA(100) : | 12.65 |
MA(250) : | 11.75 |
|
| MACD | MACD : | 1.1 |
Signal : | 1.4 |
| %K %D | K(14,3) : | 14.8 |
D(3) : | 35 |
| RSI | RSI(14): 63.1 |
|||
| 52-week | High : | 20.45 | Low : | 8.55 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ ASRT ] has closed above bottom band by 28.3%. Bollinger Bands are 23.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 18.11 - 18.2 | 18.2 - 18.27 |
| Low: | 17.76 - 17.88 | 17.88 - 17.98 |
| Close: | 17.84 - 18.02 | 18.02 - 18.17 |
Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.
Tue, 14 Apr 2026
Assertio (ASRT) divests INDOCIN, SPRIX and other brands in $35M Cosette deal - Stock Titan
Fri, 10 Apr 2026
ASRT SEC Filings - Assertio Holdings Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Thu, 09 Apr 2026
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Assertio Holdings, Inc. (NASDAQ: ASRT) - PR Newswire
Thu, 09 Apr 2026
Assertio Holdings, Inc. (NASDAQ:ASRT) Receives Average Rating of "Hold" from Brokerages - MarketBeat
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 6 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 2.5 (%) |
| Held by Institutions | 33.2 (%) |
| Shares Short | 242 (K) |
| Shares Short P.Month | 256 (K) |
| EPS | -0.32 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 14.63 |
| Profit Margin | -25.6 % |
| Operating Margin | -105.3 % |
| Return on Assets (ttm) | -4 % |
| Return on Equity (ttm) | -28.3 % |
| Qtrly Rev. Growth | -58 % |
| Gross Profit (p.s.) | 12.91 |
| Sales Per Share | 18.4 |
| EBITDA (p.s.) | 1.98 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -28 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -56.29 |
| PEG Ratio | 0 |
| Price to Book value | 1.23 |
| Price to Sales | 0.97 |
| Price to Cash Flow | -4.13 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|